Jefferies Group's ACRS Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 11,000 shares of Aclaris Therapeutics, Inc. (ACRS) worth $58,190, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in ACRS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 29,200 shares. Largest reduction occurred in Q2 2023, reducing 390,000 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Aclaris Therapeutics (ACRS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Aclaris Therapeutics (ACRS) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -2 | Reduce 0.02% | 11,000 | $3.75 |
| Q4 2025 | +2 | Add 0.02% | 11,002 | $3.01 |
| Q2 2025 | -29,200 | Reduce 72.64% | 11,000 | $1.42 |
| Q1 2025 | -500 | Reduce 1.23% | 40,200 | $1.53 |
| Q4 2024 | +29,200 | Add 253.91% | 40,700 | $2.48 |
| Q4 2023 | -25,051 | Reduce 68.54% | 11,500 | $1.05 |
| Q3 2023 | +10,000 | Add 37.66% | 36,551 | $6.85 |
| Q2 2023 | -390,000 | Reduce 93.63% | 26,551 | $10.37 |
| Q1 2023 | +416,551 | New Buy | 416,551 | $8.09 |
Jefferies Group's Aclaris Therapeutics Investment FAQs
Jefferies Group first purchased Aclaris Therapeutics, Inc. (ACRS) in Q1 2023, acquiring 416,551 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Aclaris Therapeutics, Inc. (ACRS) for 14 quarters since Q1 2023.
Jefferies Group's largest addition to Aclaris Therapeutics, Inc. (ACRS) was in Q1 2023, adding 416,551 shares worth $3.37 M.
According to the latest 13F filing for Q2 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 11,000 shares of Aclaris Therapeutics, Inc. (ACRS), valued at approximately $58,190.
As of the Q2 2026 filing, Aclaris Therapeutics, Inc. (ACRS) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Aclaris Therapeutics, Inc. (ACRS) was 416,551 shares, as reported at the end of Q1 2023.